PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2017 | 7 | 3 | 116-120
Article title

The role of activation of insulin-like growth factors in colorectal cancer

Content
Title variants
Languages of publication
EN
Abstracts
EN
Co-occurrence of metabolic disorders is a recognized risk factor for the development of colorectal cancer which is currently the leading cause of morbidity due to malignant neoplasms in the world. The pathogenesis of colorectal cancer is not well understood yet. Among the postulated neoplastic mechanisms is the activation of insulin-like growth factors, with both epidemiological and clinical observations of their role. In this paper, the authors synthesize the current knowledge about the importance of activation of insulin-like growth factors in the development of colorectal cancer.
Discipline
Publisher
Journal
Year
Volume
7
Issue
3
Pages
116-120
Physical description
References
  • 1. Krajowy Rejestr Nowotworów (KRN, National Cancer Registry) [online: http://onkologia.org.pl/] (access: December 2016).
  • 2. Baena R., Salinas P.: Diet and colorectal cancer. Maturitas. European Menopause Journal 2015; 80(3): 258-264.
  • 3. Rohdenburg G.L., Bernhard A., Krehbiel O.: Sugar tolerance in cancer. J. Am. Med. Assoc. 1919; 72: 1528-1530.
  • 4. Czyżyk A., Szczepanik Z.: Diabetes mellitus and cancer. Eur. J. Intern. Med. 2000; 11: 245-252.
  • 5. Giovanucci E.: Insulin and colon cancer. Cancer Causes & Control 1995; 6(2): 164-179.
  • 6. Gallagher E.J., LeRoith D.: Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36 (suppl. 2): 233-239.
  • 7. Godsland I.F.: Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. 2010; 118: 315-332.
  • 8. Muc-Wierzgoń M., Nowakowska-Zajdel E., Dzięgielewska-Gęsiak S. et al.: Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J. Gastroenterol. 2014; 20(29): 9759-9774.
  • 9. Hopkins B.D., Goncalves M.D., Cantley L.C.: Obesity and cancer mechanisms: cancer metabolism. J Clin. Oncol. 2016; 34(35): 4277-4283.
  • 10. Wolin K.Y., Carson K., Colditz G.A.: Obesity and cancer. Oncologist 2010; 15: 556-565.
  • 11. Campbell P.T., Newton C.C., Patel A.V. et al.: Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012; 35: 1835-1844.
  • 12. Wang L., Ma W., Markovich R. et al.: Insulin-like growth factor I modulates induction of apoptotic signalling in H9C2 cardiac muscle cells. Endocrinology 1998; 139: 1354-1360.
  • 13. Hwa V., Oh Y., Rosenfeld R.G.: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 1999; 20(6): 761-787.
  • 14. Rajah R., Katz L., Nunn S. et al.: Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog. Growth Factor Res. 1995; 6(2-4): 273-284.
  • 15. Kreitschmann-Andermahr I., Suarez P., Jennings R. et al.: GH/IGF-1 regulation in obesity-mechanisms and practical consequences in children and adults. Horm. Res. Paediatr. 2010; 73: 153-160.
  • 16. Juul A.: Serum levels of insulin-like growth factor-I and its binding proteins in health and disease. Growth. Horm. IGF Res. 2003; 13: 113-170.
  • 17. LeRoith D.: Insulin-like growth factor I receptor signalling – overlapping or redundant pathways? Endocrinology 2000; 141: 1287-1288.
  • 18. Jones J.I., Clemmons D.R.: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995; 16: 3-34.
  • 19. Suwała A., Ziora K., Landowska D.: Budowa i funkcja insulinopodobnych czynników wzrostowych oraz objawy kliniczne niedoboru IGF-1. Endokrynol. Ped. 2010; 3: 47-62.
  • 20. Filus A., Zdrojewicz Z.: Insulinopodobny czynnik wzrostu-1 (IGF-1) – budowa i rola w organizmie człowieka. Pediatr. Endocrinol. Diabetes Metab. 2014; 22(4): 161-169.
  • 21. Belfiore A.: The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des. 2007; 13(7): 671-686.
  • 22. Baxter R.C.: IGFBP Special Issue. J. Cell Commun. Signal. 2015; 9(2): DOI: 10.1007/s12079-015-0295-5.
  • 23. Józefiak A., Pacholska J., Kędzia W.: Rola IGF-1 i IGFBP w procesie neogenezy. Perinatologia, Neonatologia i Ginekologia 2008; 1: 175-183.
  • 24. Bardou M., Barkun A.N., Martel M.: Obesity and colorectal cancer. Gut. 2013; 62: 933-947.
  • 25. Cohen D.H., LeRoith D.: Obesity, type 2 diabetes and cancer: the insulin and IGF connection. Endocr. Relat. Cancer 2012; 19: 27-45.
  • 26. Suh S., Kim K.W.: Diabetes and cancer: is diabetes casually related to cancer? Diabetes Metab J. 2011; 35: 193-198.
  • 27. Renehan A.G., Frystyk J., Flyvbjerg A.: Obesity and cancer risk: the role of insulin-IGF axis. Trends Endocrinol. Metab. 2006; 17(8): 328-336.
  • 28. Walkiewicz K., Gętek M., Muc-Wierzgoń M. et al.: The importance of ADAM family proteins in malignant tumours. Post. Hig. Med. Dośw. 2016; 70: 67-73.
  • 29. Tinahones F.J., Coin-Araguez L., Mayas M.D. et al.: Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiology 2012; 12(4): DOI: 10.1186/1472-6793-12-4.
  • 30. Sax A.T., Jenkins D.G., Devin J.L. et al.: The insulin-like growth factor axis: a biological mechanism linking physical activity to colorectal cancer survival. Cancer Epidemiol. 2014; 38: 455-459.
  • 31. Parrizas M., LeRoith D.: Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997; 138: 1355-1358.
  • 32. Singh P., Alex J.M., Bast F.: Insulin receptor, and insulin-like growth factor receptor signalling systems novel treatment strategies of cancer. Med. Oncol. 2014; 31(805): DOI: 10.1007/s12032-013-0805-3.
  • 33. Nowakowska-Zajdel E., Mazurek U., Wierzgoń J. et al.: Expression of ADAM 28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int. J. Immunopathol. Pharmacol. 2013; 26: 223-228.
  • 34. Liu J.J., Druta M., Shibata D. et al.: Metabolic syndrome and colorectal cancer: is hyperinsulineamia/insulin receptor-mediated angiogenesis a critical process? J. Geriatr. Oncol. 2014; 5: 40-48.
  • 35. Hakam A., Yeatman T.J., Lu L. et al.: Expression of insulin-like growth factor receptor in human colorectal cancer. Hum. Pathol. 1999; 30(10): 1128- 1133.
  • 36. Sandhu M.S., Dunger D.B., Giovanucci E.L.: Insulin, insulin-like growth factor-1, IGF bindings proteins, their biologic interactions, and colorectal cancer. J. Natl. Cancer Inst. 2002; 94(13): 972-980.
  • 37. Durai R., Yang W., Gupta S. et al.: The role of insulin-like growth factor system in colorectal cancer: a review of current knowledge. Int. J. Colorectal Dis. 2005; 20: 203-220.
  • 38. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Jr.: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995; 16: 143-163.
  • 39. Furlanetto R.W., Harwell S.E., Frick K.K.: Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol. Endocrinol. 1994; 8: 510-517.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-84cebf54-ee1c-4e46-bdd8-b3557c5d8104
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.